COVID-19疫情对风湿病患者健康、医疗使用和行为的即时影响:国际调查结果
该国际调查通过社交媒体等渠道于2020年4月3日至5月8日收集了9300例成人风湿病患者的完整回复,评估COVID-19疫情对健康、医疗使用和行为的影响。
核心结论
- 风湿病患者在疫情期间维持治疗并遵循公共卫生建议以降低COVID-19风险。
- 就业状态发生显著变化,可能影响医疗可及性、药物可负担性、心理健康和疾病活动度。
研究设计与样本
- 通过关键利益相关方小组制定调查问题,并通过社交媒体、网站和患者支持组织全球传播。
- 纳入18岁及以上患有炎症性或自身免疫性风湿病的成人,排除仅报告纤维肌痛或骨关节炎等非炎症性风湿病者。
临床怎么用
- 疫情期间应关注风湿病患者的就业变化及其对医疗可及性、药物可负担性和心理健康的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact and consequences of the COVID-19 pandemic on people with rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance Patient Experience Survey to assess the effects of the COVID-19 pandemic on people with rheumatic disease worldwide. METHODS: Survey questions were developed by key stakeholder groups and disseminated worldwide through social media, websites, and patient support organisations. Questions included demographics, rheumatic disease diagnosis, COVID-19 diagnosis, adoption of protective behaviours to mitigate COVID-19 exposure, medication access and changes, health-care access and communication with rheumatologists, and changes in employment or schooling. Adults age 18 years and older with inflammatory or autoimmune rheumatic diseases were eligible for inclusion. We included participants with and without a COVID-19 diagnosis. We excluded participants reporting only non-inflammatory rheumatic diseases such as fibromyalgia or osteoarthritis. FINDINGS: 12 117 responses to the survey were received between April 3 and May 8, 2020, and of these, 10 407 respondents had included appropriate age data. We included complete responses from 9300 adults with rheumatic disease (mean age 46·1 years; 8375 [90·1%] women, 893 [9·6%] men, and 32 [0·3%] participants who identified as non-binary). 6273 (67·5%) of respondents identified as White, 1565 (16·8%) as Latin American, 198 (2·1%) as Black, 190 (2·0%) as Asian, and 42 (0·5%) as Native American or Aboriginal or First Nation. The most common rheumatic disease diagnoses included rheumatoid arthritis (3636 [39·1%] of 9300), systemic lupus erythematosus (2882 [31·0%]), and Sjögren's syndrome (1290 [13·9%]). Most respondents (6921 [82·0%] of 8441) continued their antirheumatic medications as prescribed. Almost all (9266 [99·7%] of 9297) respondents adopted protective behaviours to limit SARS-CoV-2 exposure. A change in employment status occurred in 2524 (27·1%) of 9300) of respondents, with a 13·6% decrease in the number in full-time employment (from 4066 to 3514). INTERPRETATION: People with rheumatic disease maintained therapy and followed public health advice to mitigate the risks of COVID-19. Substantial employment status changes occurred, with potential implications for health-care access, medication affordability, mental health, and rheumatic disease activity. FUNDING: American College of Rheumatology.
引用
- Hausmann JS, Kennedy K, Simard JF, et al. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021. PMID: 34316727. doi:10.1016/S2665-9913(21)00175-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。